Probiotics in the Prevention of Complications After Colorectal Surgery
Primary Purpose
Postoperative Complications
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Probiotics
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Complications focused on measuring Infections, anastomotic leakage
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Acceptable nutritional status and programmed for open surgery for colorectal cancer.
- Operation by the same consultant either as surgeon or as the primary assistant.
Exclusion Criteria:
- Inability to provide written informed consent
- The need only for emergency or palliative surgery
- American Society of Anaesthesiologists (ASA) class of IV
- Pregnancy or lactation
- Inflammatory bowel disease
- Use of antibiotics during the last 10 days before surgery
- Recent steroid therapy or preoperative neoadjuvant chemotherapy or radiotherapy
- Pre-existing signs of bacterial [white cell count, body temperature] or viral infection [hepatitis B or C, human immunodeficiency virus, cytomegalovirus].
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Probiotics
Arm Description
Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
Outcomes
Primary Outcome Measures
Postoperative complications
The total of postoperative complications observes in each study group. These comprise: any anastomotic leakage; abdominal wound infection and dehiscence; organ specific infections, such as pneumonia, urinary tract and central vein port-site infections, and systemic infections [bacteraemia, fungal infections] as regularly defined by positive cultures, radiograms, increased white blood cell count or purulent material discharge; sepsis and septic shock
Secondary Outcome Measures
Minor complications
Rate of minor events in each group. These comprise peripheral vein thrombosis or pulmonary embolism and cardio-pulmonary or renal insufficiency. Moreover, the number of days on mechanical ventilation, in postoperative ileus, of total hospitalization, as well as 30-day mortality is taken into account.
Cytokine levels
Measurement of serum cytokines in subgroups of patients
Cytokine gene transcripts
Measurement of gene transcripts in whole blood in subgroups of patients
Full Information
NCT ID
NCT02313519
First Posted
December 8, 2014
Last Updated
December 9, 2014
Sponsor
Evangelos J. Giamarellos-Bourboulis, M.D.
Collaborators
Aristotle University Of Thessaloniki
1. Study Identification
Unique Protocol Identification Number
NCT02313519
Brief Title
Probiotics in the Prevention of Complications After Colorectal Surgery
Official Title
A Randomized Clinical Study of the Efficacy of a Formulation of Four Probiotics for the Prevention of Post-operative Complications in Patients Undergoing Colorectal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
August 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Evangelos J. Giamarellos-Bourboulis, M.D.
Collaborators
Aristotle University Of Thessaloniki
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Based on the need of large-scale, trials to explore the use of probiotics to reduce post-operative complication rate, a randomized controlled trial is designed to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is reduction of post-operative complications after 30 days.
Detailed Description
Major colorectal surgery, i.e. surgery involving a wide colon resection and/or a very low anastomosis, remains problematic, despite great advances in medico-pharmaceutical treatment, improvement in surgical techniques, and sophisticated postoperative management. Such surgery is still accompanied by an unacceptably high morbidity of 15% to 23.2% leading to an increase in the number of ventilatory support days, prolongation of total hospital stay, significantly higher medical costs, patient suffering, and, unfortunately mortality. Worse than this, nowadays, infections and sepsis are by far the most common morbidities, either as initial cause or as a consequence of another complication, such as anastomotic leakage. Ongoing clinical studies have reported probiotic therapies to be beneficial in elective surgery cases, since they have been shown to successfully modulate the GI flora in a plethora of medical settings and in critically ill and trauma patients. More precisely, recent randomized controlled studies and meta-analyses in elective surgery and abdominal surgery patients have demonstrated that the perioperative use of probiotics is safe and reduces both the incidence of postoperative wound infections, sepsis, post-operative pneumonia and other infections, and the necessary duration of hospital stay and length of antibiotic therapy. However, there exist few controlled, large-scale, trials comparing the current standard treatment with the probiotic concept and showing the superiority of the latter in colonic surgery with regard to a reduced complication rate. Therefore, the investigators decided to conduct a randomized controlled trial to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is to evidence a reduction in 30-day infectious, surgery-related morbidity: any surgical site infection; organ specific infections; systemic infections and anastomotic leakage. Minor objectives related to the reduction in other non-infectious complications, as well as the assessment of outcome indicators such as the number of days in postoperative ileus, on mechanical ventilation, stay in ICU, total hospitalization and mortality in the 30-day post-operative period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Complications
Keywords
Infections, anastomotic leakage
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
164 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
Arm Title
Probiotics
Arm Type
Active Comparator
Arm Description
Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotics
Other Intervention Name(s)
Lactobacillus, Bifidobacterium and Saccharomyces boulardii
Intervention Description
Probiotics are prepared in capsule form
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo capsules
Intervention Description
Glucose powder
Primary Outcome Measure Information:
Title
Postoperative complications
Description
The total of postoperative complications observes in each study group. These comprise: any anastomotic leakage; abdominal wound infection and dehiscence; organ specific infections, such as pneumonia, urinary tract and central vein port-site infections, and systemic infections [bacteraemia, fungal infections] as regularly defined by positive cultures, radiograms, increased white blood cell count or purulent material discharge; sepsis and septic shock
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Minor complications
Description
Rate of minor events in each group. These comprise peripheral vein thrombosis or pulmonary embolism and cardio-pulmonary or renal insufficiency. Moreover, the number of days on mechanical ventilation, in postoperative ileus, of total hospitalization, as well as 30-day mortality is taken into account.
Time Frame
30 days
Title
Cytokine levels
Description
Measurement of serum cytokines in subgroups of patients
Time Frame
4 days
Title
Cytokine gene transcripts
Description
Measurement of gene transcripts in whole blood in subgroups of patients
Time Frame
4 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent
Acceptable nutritional status and programmed for open surgery for colorectal cancer.
Operation by the same consultant either as surgeon or as the primary assistant.
Exclusion Criteria:
Inability to provide written informed consent
The need only for emergency or palliative surgery
American Society of Anaesthesiologists (ASA) class of IV
Pregnancy or lactation
Inflammatory bowel disease
Use of antibiotics during the last 10 days before surgery
Recent steroid therapy or preoperative neoadjuvant chemotherapy or radiotherapy
Pre-existing signs of bacterial [white cell count, body temperature] or viral infection [hepatitis B or C, human immunodeficiency virus, cytomegalovirus].
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katerina Kotxampassi, MD, PhD
Organizational Affiliation
AXEPA University of Thessaloniki, 1st Department of Propedeutic Surgery, Thessaloniki, Greece
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Evangelos Giamarellos-Bourboulis, MD, PhD
Organizational Affiliation
University of Athens, 4th Department of Internal Medicine, Athens, Greece
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
19820590
Citation
Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K. Pro- and synbiotics to control inflammation and infection in patients with multiple injuries. J Trauma. 2009 Oct;67(4):815-21. doi: 10.1097/TA.0b013e31819d979e.
Results Reference
background
PubMed Identifier
16983476
Citation
Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J Surg. 2006 Oct;30(10):1848-55. doi: 10.1007/s00268-005-0653-1.
Results Reference
background
PubMed Identifier
25894405
Citation
Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, Giamarellos-Bourboulis EJ. A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. World J Surg. 2015 Nov;39(11):2776-83. doi: 10.1007/s00268-015-3071-z.
Results Reference
derived
Learn more about this trial
Probiotics in the Prevention of Complications After Colorectal Surgery
We'll reach out to this number within 24 hrs